

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Letermovir. [Updated 2019 Feb 7]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Letermovir

Revised: February 7, 2019.

CASRN: 917389-32-3

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of letermovir during breastfeeding. Because letermovir is 99% bound to plasma proteins, the amount in milk is likely to be very low. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Letermovir

CAS Registry Number

917389-32-3

Drug Class

Breast Feeding

Lactation

Anti-Infective Agents

Antiviral Agents